KASMEJ
Kastamonu Medical Journal

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

eISSN: 2757-9336
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of patients diagnosed with intermediate - high risk pulmonary thromboembolism
Abstract
Aims: In this study we aimed to share our treatment approach in patients with intermediate -high risk pulmonary embolism (PE).
Methods: This is a single center retrospective observational study. Patients diagnosed with PE at Akdeniz University Hospital between January 1, 2015, and January 1, 2021, were retrospectively analyzed. Patients whose diagnosis of PE was confirmed by computed tomography angiography (CTA) or perfusion/ventilation scintigraphy were considered to have PE. Patients with intermediate-high risk were included in the study. Patients with a diagnosis of low-risk, low-intermediate risk, high-risk PE, patients younger than 18 years of age, and pregnant were excluded from the study.
Results: A total of 150 patients, 64 (42.7%) male and 86 (57.3%) female, with a mean age of 62.2±16.2 years, who met the criteria of these patients were included. 22.7% (34) of the patients received thrombolytic therapy. While 67.7% (23) of the patients who received thrombolytic therapy received half-dose (50mg rt-PA) thrombolytic therapy, 32.3% (11) received full-dose (100mg rt-PA) thrombolytic therapy. Major hemorrhage (3 intracranial hemorrhages, 1 femoral hemorrhage) was detected in 11.7% (4) of the patients who received thrombolytic therapy.
Conclusion: In conclusion, no significant effect of thrombolytic therapy or full or half dose on mortality and long-term TTE findings was found in the intermediate -high risk group.

Keywords : Pulmonary embolism, thrombolytic, intermediate -high risk

Download Article


1. 2019 ESC Guidelines for the diagnosis and management of acutepulmonary embolism developed in collaboration with the EuropeanRespiratory Society (ERS) | European Heart Journal | Oxford Academic[İnternet]. [a.yer 10 Kasım 2022]. Erişim adresi: https://academic.oup.com/eurheartj/article/41/4/543/5556136
2. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402- 1411. https://doi: 10.1056/NEJMoa1302097
3. Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: The SEATTLE II Study. JACC Cardiovasc Interv. 2015;8(10):1382-1392. https://doi: 10.1016/j.jcin.2015.04.020
4. Casazza F, Becattini C, Bongarzoni A, Cuccia C, Roncon L, FavrettoG, vd. Clinical features and short term outcomes of patients with acutepulmonary embolism. The Italian Pulmonary Embolism Registry (IPER).Thromb Res. 2012;130(6):847-52.
5. Piazza G. Advanced Management of Intermediate- and High-RiskPulmonary Embolism: JACC Focus Seminar. J Am Coll Cardiol.2020;76(18):2117-27.
6. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, RondinaMT, vd. Treatment of submassive pulmonary embolism with tenecteplaseor placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost JTH.2014;12(4):459-68.
7. Weinstein T, Deshwal H, Brosnahan SB. Advanced management ofintermediate-high risk pulmonary embolism. Crit Care Lond Engl.2021;25(1):311.
8. Kiser TH, Burnham EL, Clark B, Ho PM, Allen RR, Moss M, vd. Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism*.Crit Care Med. 2018;46(10):1617-25.
9. Tapson VF, Weinberg AS. Overview of Management of Intermediate- andHigh-Risk Pulmonary Embolism. Crit Care Clin. 2020;36(3):449-63.
Article available in :
Volume 3, Issue 1, 2023
Page : 37-40
https://doi.org/10.51271/KMJ-0093
Article Information
Received : 19 Ara 2022
Accepted : 27 Şub 2023
Published : 21 Mar 2023
Corresponding Author :

Fatih Üzer: Department of Chest Diseases, Akdeniz University Faculty of Medicine, Antalya, Türkiye

[email protected]
Citation : Çiçek S, Üzer F, Özdemir T. Evaluation of patients diagnosed with intermediate -high risk pulmonary thromboembolism. Kastamonu Med J. 2023; 3(1): 37-40

Read: 354
Cited: 0
Download : 416
_Footer